RPL17 and plasma cell myeloma: Receiver Operating Characteristic (ROC) curve analysis has shown that among different MPs and immune cells, PMP, CD138+MP, PD1+CD8+T cells, PD1+CD4+T cells, and CD8+T have shown good accuracy in predicting the response to Bortezomib based combination in patients with MM as illustrated in Table 6, and Fig. 7, the largest AUC was observed with PD1+CD4+T cells for predicting non CR among active myeloma patients (AUC = 0.94, p = 0.0001) with the highest sensitivity (92%), specificity (80%), and performance (72%).